Herpes simplex vaccines

Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis

Volumn , Issue , 2007, Pages 1253-1261

  Kemble, George ^a   Spaete, Richard ^a  

^a MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84890731721     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511545313.070     Document Type: Chapter

References (53)

1. Armstrong, G. L., Schillinger, J., Markowitz, L. et al. (2001). Inci-dence of herpes simplex virus type 2 infection in the United States.’ Am. J. Epidemiol., 153(9), 912-920.
2. Arvin, A. M. and Prober, C. G. (1997). Herpes simplex virus Type 2-a persistent problem. N. Engl. J. Med., 337, 1158-1159.
3. Barcy, S. and Corey, L. (2001). Herpes simplex inhibits the capac-ity of lymphoblastoid B cell lines to stimulate CD4+ T cells. J. Immunol., 166(10): 6242-6249.
4. BenMohamed, L., Bertrand, G., McNamara, C. D. et al. (2003). Identification of novel immunodominant CD4+ Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity. J. Virol., 77(17), 9463-9473
5. Bourne, N., Bravo, F. J., Francotte, M. et al. (2003). Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and pro-tection against genital HSV-1 or HSV-2 disease in guinea pigs. J. Infect. Dis., 187(4), 542-549.
6. Boursnell, M. E., Entwisle, C., Blakeley, D. et al. (1997). A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine pro-vides effective protection against primary and recurrent HSV-2 disease. J. Infect. Dis., 175(1), 16-25.
7. Brown, Z. A., Selke, S., Zeh, J. et al. (1997). The acquisition of herpes simplex virus during pregnancy. N. Engl. J. Med., 337(8), 509-515.
8. Brown, Z. A., Wald, A., Morrow, R. A., Selke, S., Zeh, J., and Corey, L. (2003). Effectofserologicstatusandcesareandeliveryontrans-mission rates of herpes simplex virus from mother to infant. J. Am. Med. Assoc., 289(2), 203-209.
9. Burke, R. L. (1993). Current status of HSV vaccine development. In The Human Herpesviruses. R. J. W. a. C. L. B. Roizman. New York, Raven Press, pp. 367-379.
10. Cadoz, M., Micoud, M., Mallaret, M. et al. (1992). Phase 1 trial of R7020: A live attenuated recombinant herpes simplex (HSV) candidate vaccine. ICAAC Washington DC (Abstract).
11. Chou, J., Kern, E. R., Whitley, R. J., and Roizman, B. (1990). Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science, 250(4985), 1262-1266.
12. Corey, L., Langenberg, A. G., Ashley, R. et al. (1999). Recombi-nant glycoprotein vaccine for the prevention of genital HSV-2 infection: Two randomized controlled trials. Chiron HSV Vac-cine Study Group. J. Am. Med. Assoc., 282(4), 331-340.
13. Da Costa, X. J., Bourne, N., Stanberry, L. R., and Knipe, D. M. (1997). Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immu-nization studies in a guinea pig model of genital disease. Virology, 232(1), 1-12.
14. Da Costa, X. J., Jones, C. A., and Knipe, D. M. (1999). Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection. Proc. Natl Acad. Sci. USA, 96(12), 6994-6998.
15. Farrell, H. E., McLean, C. S., Harley, C., Efstathiou, S., Inglis, S., and Minson A. C. (1994). Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted. J. Virol., 68(2), 927-932.
16. Fleming, D. T., McQuillan, G. M., Johnson, R. E. et al. (1997). Herpes simplex virus type 2 in the United States, 1976 to 1994. N. Engl. J. Med., 337(16), 1105-1111.
17. Flo, J., Tisminetzky, S., and Baralle, F. (2001). Oral transgene vac-cination mediated by attenuated Salmonellae is an effective method to prevent Herpes simplex virus-2 induced disease in mice. Vaccine, 19(13-14), 1772-1782.
18. Galloway, D. A. (2003). Papillomavirus vaccines in clinical trials. Lancet. Infect. Dis., 3(8), 469-475.
19. Gierynska, M., Kumaraguru, U., Eo, S. K., Lee, S., Krieg, A., and Rouse, B. T. (2002). Induction of CD8 T-cell-specific systemic and mucosal immunity against herpes simplex virus with CpG-peptide complexes. J. Virol., 76(13), 6568-6576.
20. Gyotoku, T., Ono, F., and Aurelian, L. (2002). Development of HSV-specific CD4+ Th1 responses and CD8+ cyto-toxic T lymphocytes with antiviral activity by vaccination with the HSV-2 mutant ICP10DeltaPK. Vaccine, 20(21-22), 2796-2807.
21. Hegde, N. R., Chevalier, M. S., and Johnson, D. C. (2003). Viral inhi-bition of MHC class II antigen presentation. Trends Immunol., 24(5), 278-285.
22. Heineman, T. C., Connelly, B. L., Bourne, N., Stanberry, L. R., and Cohen, J. (1995). Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycopro-tein D reduces the severity of genital herpes in guinea pigs., J. Virol., 69(12), 8109-8113.
23. Holmberg, S. D., Stewart, J. A., Gerber, A. R. et al. (1988). Prior herpes simplex virus type 2 infection as a risk factor for HIV infection. J. Am. Med. Assoc., 259(7), 1048-1050.
24. Johnson, D. C. and Hill, A. B. (1998). Herpesvirus evasion of the immune system. Curr. Top. Microbiol. Immunol., 232, 149-177.
25. Kimberlin, D. W., Lin, C. Y., Jacobs, R. F. et al. (2001). Natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics, 108(2), 223-229.
26. Kohl, S., Charlebois, E. D., Sigouroudinia, M. et al. (2000). Limited antibody-dependent cellular cytotoxicity antibody response induced by a herpes simplex virus type 2 subunit vaccine., J. Infect. Dis., 181(1), 335-339.
27. Koutsky, L. A., Ault, K. A., Wheeler, C. M. et al. (2002). A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med., 347(21), 1645-1651.
28. Langenberg, A. G., Burke, R. L., Adair, S. F. et al. (1995). A recom-binant glycoprotein vaccine for herpes simplex virus type 2: Safety and immunogenicity [corrected]. Ann. Intern. Med., 122(12), 889-898.
29. Langenberg, A. G., Corey, L., Ashley, R. L., Leong, W. P., and Straus, S. E. (1999). A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N. Engl. J. Med., 341(19), 1432-1438.
30. Leib, D. A. (2002). Counteraction of interferon-induced antiviral responses by herpes simplex viruses. Curr. Top. Microbiol. Immunol., 269, 171-185.
31. Lorenzo, M. E., Ploegh, H. L., and Tirabassi, R. S. (2001). Viral immune evasion strategies and the underlying cell biology. Semin. Immunol., 13(1), 1-9.
32. McLean, C. S., Erturk, M., Jennings, R. et al. (1994). Protective vacci-nation against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1. J. Infect. Dis., 170(5), 1100-1109.
33. Meignier, B., Longnecker, R., and Roizman, B. (1988). In vivo behav-ior of genetically engineered herpes simplex viruses R7017 and R7020: Construction and evaluation in rodents. J. Infect. Dis., 158(3), 602-614.
34. Meignier, B., Martin, B., Whitley, R. J., and Roizman, B. (1990). In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J. Infect. Dis., 162(2), 313-321.
35. Mohr, I., Sternberg, D., Ward, S., Leib, D., Mulvey, M., and Gluzman, Y. (2001). A herpes simplex virus type 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals. J. Virol., 75(11), 5189-5196.
36. Murphy, C. G., Lucas, W. T., Means, R. E. et al. (2000). Vac-cine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus. J. Virol., 74(17), 7745-7754.
37. O'Hagan, D., Goldbeck, C., Ugozzoli, M., Ott, G., and Burke, R. L. (1999). Intranasal immunization with recombinant gD2 reduces disease severity and mortality following genital chal-lenge with herpes simplex virus type 2 in guinea pigs. Vaccine, 17(18), 2229-2236.
38. Prichard, M. N., Kaiwar, R., Jackman, W. T. et al. (2005). Eval-uation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs. Vaccine, 23, 5424-5431.
39. Rees, R. C., McArdle, S., Mian, S. et al. (2002). Disabled infectious single cycle-herpes simplex virus (DISC-HSV) as a vector for immunogene therapy of cancer. Curr. Opin. Mol. Ther., 4(1), 49-53.
40. Ribes, J. A., Steele, A. D., Seabolt, J. P., and Baker, D. J. (2001). Six-year study of the incidence of herpes in genital and nongenital cul-tures in a central Kentucky medical center patient population. J. Clin. Microbiol., 39(9), 3321-3325.
41. Simms, J. R., Heath, A. W., and Jennings, R. (2000). Use of her-pes simplex virus (HSV) type 1 ISCOMS 703 vaccine for pro-phylactic and therapeutic treatment of primary and recur-rent HSV-2 infection in guinea pigs. J. Infect. Dis., 181(4), 1240-1248.
42. Spear, P. (1985). Glycoproteins specified by Herpes simplex viruses. In Roizman, B., ed. The Herpesviruses. New York: Plenum, 3, 315-356.
43. Spector, F. C., Kern, E. R., Palmer, J. et al. (1998). Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs. J. Infect. Dis., 177(5), 1143-1154.
44. Stanberry, L., Cunningham, A., Mertz, G. (1999). New developments in the epidemiology, natural history and management of gen-ital herpes. Antiviral Res., 42(1), 1-14.
45. Stanberry, L. R., Spruance, S. L., Cunningham, A. L. et al. (2002). Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med., 347(21), 1652-1661.
46. Strasser, J. E., Arnold, R. L., Pachuk, C., Higgins, T. J., and Bernstein, D. I. (2000). Herpes simplex virus DNA vaccine efficacy: Effect of glycoprotein D plasmid constructs. J. Infect. Dis., 182(5), 1304-1310.
47. Stratton, K., Durch, J., and Lawrence, R. eds. (2000). Vaccines for the 21st Century. A Tool for Decision Making. Washington, DC: National Academy Press.
48. Straus, S. E., Wald, A., Kost, R. G. et al. (1997). Immunotherapy of recurrent genital herpes with recombinant herpes sim-plex virus type 2 glycoproteins D and B: Results of a placebo-controlled vaccine trial. J. Infect. Dis., 176(5), 1129-1134.
49. Varghese, S. and Rabkin, S. D. (2002). Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther., 9(12), 967-978.
50. Wald, A., Zeh, J., Selke, S., Ashley, R. L., and Corey, L. (1995). Virologic characteristics of subclinical and symptomatic genital herpes infections. N. Engl. J. Med., 333(12), 770-775.
51. Whitley, R. J. (2001). Herpes simplex viruses. In Knipe, D. M. and Howley, P. M., eds. Fields Virology, 4thedn. Lippincott, Williams & Wilkins, 2.
52. Whitley, R. J., Kern, E. R., Chatterjee, S., Chou, J., and B. Roizman (1993). Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models. J. Clin. Invest., 91(6), 2837-2843.
53. Xu, F., Schillinger, J. A., Sternberg, M. R. et al. (2002). Seropreva-lence and coinfection with herpes simplex virus type 1 and type 2 in the United States, 1988-1994. J. Infect. Dis., 185(8), 1019-1024.